The medicines business | A question to investigate
When quality becomes a capital decision
The most important manufacturing investment can be the one that prevents a familiar problem returning. Yet the board paper may show the equipment price more clearly than the cost of repeated investigation, unstable capacity or delayed supply. NEUVIOR is interested in that gap: helping a manufacturer frame a quality investment around the decision people actually need to make, with production, quality and finance able to challenge the same assumptions.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
A problem that crosses three desks
Consider a recurring deviation that consumes technical time without stopping every batch. Quality sees investigation depth; operations sees interrupted schedules; finance sees expenditure that competes with another project. Combining those views does not mean placing a price on compliance. It means separating the mandatory response from discretionary investment options, then identifying which uncertainty prevents an informed choice. An intervention can be necessary without its proposed scale, timing or commercial return already being established.
The starting standard
MHRA describes GMP as the minimum manufacturing standard (MHRA, 2014). FDA’s Quality Management Maturity programme considers practices beyond CGMP (FDA, n.d.). These are distinct regulatory contexts, not interchangeable certifications. Our proposed decision work would sit alongside the organisation’s existing quality system. The first question is therefore practical: which activities must happen regardless of the investment case, and which alternatives can legitimately be compared by the people authorised to decide?
Compare the actual alternatives
Replacing a line, adding monitoring, changing maintenance, building workforce capability and continuing with additional controls are different propositions. A fair comparison describes the same production scope and time horizon for each. Installation downtime belongs in the calculation, as do validation work, training, ongoing servicing and dependence on a sole supplier. A technically attractive option can create a new operational bottleneck. A cheaper option can defer the original problem without resolving it.
The investment question in one view
The proposed deliverable would separate compulsory remediation, optional investment and the evidence still needed to choose between options. It would show the assumptions that determine the preferred route and name the owner who can confirm each one. That gives a capital committee something more useful to challenge than a single return estimate.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A medicines or implementation team considering an AI-supported evidence review.
Would a quicker review make the decision better?
The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.
A proposition to investigate
Less preparation. The same ability to challenge.
An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.
The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether one defined review task merits an agreed evaluation.
- The comparator
- The team's existing complete review process, including checking and corrections.
- The evidence
- Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
- Stop or redesign
- Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefA bounded PHARMORIS evaluation
We would propose one decision involving a defined product family or process step. Inputs could include approved deviation summaries, recurring investigation categories, capacity assumptions, maintenance plans and finance-approved cost ranges. Identifiable patient information is unlikely to be needed for this first question. The comparator would be the organisation’s usual investment paper, assessed against an evidence-linked decision brief. Quality approval and any batch disposition would remain entirely within the manufacturer’s authorised processes.
What the evaluation would measure
Useful measures include the proportion of material assumptions with an accountable owner, the number of unresolved dependencies recognised before approval, reviewer correction time and the reproducibility of the comparison. These are decision-process measures. They do not establish improved product quality or fewer shortages. Those outcomes would require a separate, appropriately designed follow-up with a credible baseline, enough observation time and attention to other operational changes taking place simultaneously.
A business case that can fail honestly
The analysis should show where the preferred option changes when downtime, implementation cost or expected recurrence changes. If modest assumption changes reverse the choice, further information may be more valuable than immediate capital expenditure. We would pause if the records cannot distinguish recurring events from duplicated reporting, if essential quality decisions are being delegated to an unqualified output, or if the comparator is deliberately weakened. A negative finding should remain usable by the board.
The conversation worth having
For a manufacturing leader, the opportunity is a clearer investment conversation between people who carry different responsibilities. For a quality leader, it is visibility of assumptions that commercial pressure might otherwise obscure. A useful first discussion would bring one unresolved decision, its owner, the options currently under consideration and the date a decision is needed. That is enough to explore whether a narrowly scoped evaluation could add value before anyone commits to a wider programme.
Sources and scope
MHRA | Good manufacturing and distribution practice | FDA | Quality Management Maturity
MHRA (2014) Good manufacturing and distribution practice. Available at: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice (Accessed: 14 October 2026).
FDA (n.d.) Quality Management Maturity. Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/cder-quality-management-maturity (Accessed: 14 October 2026).
Another useful angle.
- Which supply exception deserves attention first?
Explore a proposed wholesale exception-review evaluation that compares effort, escalation and operational consequences.
- When the temperature moves, the evidence must keep up
A proposed cold-chain evidence-preparation review for accountable medicines quality teams.
- Before a shortage becomes everybody’s problem
A proposed readiness review for marketing authorisation holders connecting supply evidence, reporting ownership and action.